The Senior Leadership of the Virginia Commonwealth University (VCU) Massey Cancer Center (MCC) consists of the Director, scientific Associate Directors for Basic, Translational, Clinical, Cancer Prevention and Control Research, as well as an Associate Director for Shared Resources and an Associate Director for Research Administration and Finance. As a group, these leaders are responsible for the strategic scientific planning and tactical development of the MCC. Each of the Associate Directors provides direction for his or her area and promotes collaboration among the various areas. This Senior Leadership is complemented by the MCC strategy of Co-Leadership in each of the research programs. The translational programs have a basic science and clinical science teams of Co-Leaders, while the basic science programs are lead by Co- Leaders who have a major basic science research focus. The strength of this approach is manifested by the success of our scientific programs, as demonstrated in the overall growth of our cancer-focused research base and early phase clinical trials and translational research developed by our investigators. The Senior Leadership team is a stable, highly cohesive group of senior level cancer researchers who have successfully guided the MCC through its recent major growth in high impact collaborative scientific research and translational and clinical trial activities and established a strong positive trajectory for the future.
The Senior Leadership of MCC is instrumental in assuring that MCC fulfills its mission as an NCI-designated cancer center. The Senior Leadership develops and implements the strategic plans that facilitate the basic, translational, and clinical research and transdisciplinary interactions of the MCC members, thus serving the public health mission of detecting, treating, and eliminating cancer.
|Ding, Boxiao; Parmigiani, Anita; Divakaruni, Ajit S et al. (2016) Sestrin2 is induced by glucose starvation via the unfolded protein response and protects cells from non-canonical necroptotic cell death. Sci Rep 6:22538|
|Terracina, Krista P; Graham, Laura J; Payne, Kyle K et al. (2016) DNA methyltransferase inhibition increases efficacy of adoptive cellular immunotherapy of murine breast cancer. Cancer Immunol Immunother 65:1061-73|
|Alotaibi, Moureq; Sharma, Khushboo; Saleh, Tareq et al. (2016) Radiosensitization by PARP Inhibition in DNA Repair Proficient and Deficient Tumor Cells: Proliferative Recovery in Senescent Cells. Radiat Res 185:229-45|
|Truchan, Hilary K; Cockburn, Chelsea L; Hebert, Kathryn S et al. (2016) The Pathogen-Occupied Vacuoles of Anaplasma phagocytophilum and Anaplasma marginale Interact with the Endoplasmic Reticulum. Front Cell Infect Microbiol 6:22|
|Menezes, M E; Das, S K; Minn, I et al. (2016) Detecting Tumor Metastases: The Road to Therapy Starts Here. Adv Cancer Res 132:1-44|
|Agarwal, Stuti; Bell, Catherine M; Taylor, Shirley M et al. (2016) p53 Deletion or Hotspot Mutations Enhance mTORC1 Activity by Altering Lysosomal Dynamics of TSC2 and Rheb. Mol Cancer Res 14:66-77|
|Gewirtz, David A (2016) The Challenge of Developing Autophagy Inhibition as a Therapeutic Strategy. Cancer Res 76:5610-5614|
|Lafata, Jennifer Elston; Shay, L Aubree; Brown, Richard et al. (2016) Office-Based Tools and Primary Care Visit Communication, Length, and Preventive Service Delivery. Health Serv Res 51:728-45|
|Korwar, Sudha; Morris, Benjamin L; Parikh, Hardik I et al. (2016) Design, synthesis, and biological evaluation of substrate-competitive inhibitors of C-terminal Binding Protein (CtBP). Bioorg Med Chem 24:2707-15|
|Ge, Xiuchun; Shi, Xiaoli; Shi, Limei et al. (2016) Involvement of NADH Oxidase in Biofilm Formation in Streptococcus sanguinis. PLoS One 11:e0151142|
Showing the most recent 10 out of 413 publications